Project Grant HT9425261E446
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $5.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
- The Defense Health Agency awarded The Rockefeller University $1.649998 million on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct therapeutic targeting of a commonly inherited breast cancer metastasis driver gene. Work performance is located in New York, NY with a period of performance through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded George Mason University $501,515 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of PIK3CA mutations in tumorigenesis of HER2-positive breast cancer. Work is performed in Fairfax, Virginia, with a period of performance through August 31, 2029. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced...
- The Defense Health Agency awarded University of California, San Diego $1.65 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research targeting oncoembryonic antigens to overcome therapy resistance in patients with triple-negative breast cancer. The award is a Project Grant with a period of performance from May 1, 2026, through April 30, 2029. Work is performed in La Jolla, California. The Military Medical Research and Development...
- The Defense Health Agency awarded the Beckman Research Institute of the City of Hope $416,217 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop photoacoustic computed tomography technology for identifying and diagnosing axillary lymph nodes in breast cancer patients without surgery. Performance runs through September 29, 2029, at the Institute's Irwindale, California research facility. The Military Medical Research and Development program...
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded Brigham & Women's Hospital Inc. $3.5 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research activating a B cell response against breast cancer. The award supports a three-year period of performance from September 1, 2026, through August 31, 2029, with work performed in Boston, Massachusetts. The Military Medical Research and Development program funds basic, applied, and advanced...
- The Defense Health Agency awarded the University of Melbourne $1,121,554 on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel biological therapies targeting a tumor-specific isoform of HER2 for treatment of advanced breast cancer. The award obligates $1,121,554 through March 31, 2029. Work is performed in Australia. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform...
- The Defense Health Agency awarded the University of Pittsburgh $1.8 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate mechanisms and develop innovative therapies for ESR1-CCDC170 fusions in clinically aggressive, endocrine-resistant, and metastatic breast cancers. The award supports a three-year project period ending April 30, 2029, with work performed at the University of Pittsburgh in Pittsburgh, Pennsylvania. The Military...
- The Defense Health Agency awarded The University of Texas Southwestern Medical Center $1,699,998 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to map, characterize, and elucidate the clinical relevance of driver enhancers in lethal prostate cancer. Work is performed in Dallas, Texas, with a period of performance through June 14, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to...